HSBC Holdings
RUBY

HSBC Holdings’s Rubius Therapeutics, Inc RUBY Stock Holding History

HSBC Holdings’s Portfolio RUBY Stock Details RUBY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-41,457
Closed -$313K – 3240
2020
Q4 		$313K Buy
41,457
+23,260
+128% +$138K ﹤0.01% 2545
2020
Q3 		$92K Buy
18,197
+3,774
+26% +$20K ﹤0.01% 2633
2020
Q2 		$86K Buy
+14,423
New +$85.1K ﹤0.01% 2540
2019
Q4 		– Sell
-14,145
Closed -$111K – 3240
2019
Q3 		$111K Buy
+14,145
New +$165K ﹤0.01% 2971

Other funds holding RUBY

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
AFM
Abbot Financial Management Andover, Massachusetts $239M AUM 27.19% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

HSBC Holdings's RUBY Position: Q1 2021 in Review

HSBC Holdings sold out of Rubius Therapeutics, Inc (RUBY) in Q1 2021, closing a stake of 41,457 shares — an estimated $313K sold.

HSBC Holdings first reported a position in RUBY in Q3 2019 and held it in 4 quarters. The position peaked at $313K in Q4 2020. 105 funds tracked by Wall St. Rank hold RUBY as of Q1 2021.

  • HSBC Holdings reported no remaining Rubius Therapeutics, Inc position as of Q1 2021 after selling out during the quarter.
  • HSBC Holdings sold 41,457 Rubius Therapeutics, Inc shares in Q1 2021, an estimated $313K.
  • HSBC Holdings first reported a position in Rubius Therapeutics, Inc in Q3 2019 and held it in 4 quarters.
  • HSBC Holdings's Rubius Therapeutics, Inc position peaked at $313K in Q4 2020.
  • 105 funds tracked by Wall St. Rank held Rubius Therapeutics, Inc as of Q1 2021.

Based on HSBC Holdings's 13F filing for Q1 2021, filed 14 May 2021.